When evaluating CJC-1295 price structures for empirical research, acquisition decisions must balance unit cost against analytical purity, batch-to-batch consistency, and rigorous third-party validation. This guide outlines the key variables influencing synthesis cost, structural distinctions between DAC and non-DAC variants, and quality assurance protocols necessary for reliable in vitro and preclinical experimentation.
When evaluating CJC-1295 price structures for empirical research, acquisition decisions must balance unit cost against analytical purity, batch-to-batch consistency, and rigorous third-party validation. This guide outlines the key variables influencing synthesis cost, structural distinctions between DAC and non-DAC variants, and quality assurance protocols necessary for reliable in vitro and preclinical experimentation.
The price of CJC-1295 for laboratory research is primarily governed by chemical synthesis complexity, sequence length, modification state (such as the presence of the Drug Affinity Complex or DAC), manufacturing scale, and the extent of analytical quality control. High-purity CJC-1295 verified via RP-HPLC and ESI-MS commands pricing reflective of ISO 17025 lab testing, lot-specific COAs, and stringent endotoxin controls.
Investigators seeking reliable data must evaluate cost alongside verification standards. Lower raw pricing often correlates with unverified purity, persistent truncated peptide impurities, or unmeasured bioburden levels that compromise cell culture viability and preclinical model fidelity. For research teams scaling up experiments, accessing transparent pricing structures through wholesale lab accounts ensures consistent supply chain integrity without sacrificing analytical standards.
CJC-1295 is a synthetic 29-amino-acid tetrasubstituted analog of human growth hormone-releasing hormone (GHRH 1-29). In preclinical literature, the compound is characterized by specific amino acid substitutions at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These structural modifications enhance enzymatic stability, rendering the peptide significantly more resistant to dipeptidyl peptidase-IV (DPP-IV) cleavage compared to native GHRH.
As a potent target of the pituitary GHRH receptor, CJC-1295 acts as a long-acting secretagogue. Preclinical studies suggest that binding to the GHRH receptor triggers intracellular cAMP accumulation and downstream activation of the protein kinase A (PKA) pathway, which stimulates somatotroph cells to synthesize and release endogenous growth hormone (GH). Subsequent systemic elevation of GH drives hepatic secretion of insulin-like growth factor 1 (IGF-1), establishing a primary mechanism for examining cellular growth, protein translation, and tissue repair pathways.
To explore detailed physiological assays and kinetic modeling of GHRH receptor agonists, researchers can review our broader repository of technical documentation in the PX1 Research Library hub.
A critical factor in determining research utility and unit pricing is whether the peptide incorporates the Drug Affinity Complex (DAC). CJC-1295 with DAC includes a maleimidopropionic acid reactive group covalently attached to the Lys29 residue. This moiety forms a stable covalent bond with circulating plasma albumin in vivo, extending the biological half-life from approximately 30 minutes to over 6–8 days in preclinical models.
Conversely, CJC-1295 without DAC—frequently designated as Modified GRF 1-29—lacks the reactive linker. While it retains the enzymatic resistance provided by the four amino acid substitutions, its biological clearance rate is substantially faster, yielding transient, pulsatile GH release rather than sustained elevation. To inspect individual technical specifications and batch options, researchers can consult the dedicated catalog entry for CJC-1295 DAC.
From a procurement perspective, the additional chemical coupling steps and specialized purification required for the DAC modification increase manufacturing costs. However, because CJC-1295 DAC provides prolonged exposure in long-term cellular or animal models, total assay volume requirements may be reduced over multi-week experimental protocols, altering the overall cost-per-assay calculation.
In vitro data indicate that sustained activation of the GHRH receptor by CJC-1295 modulates several downstream transcription factors involved in extracellular matrix remodeling and cell proliferation. Rodent models evaluating tissue repair mechanisms demonstrate that sustained IGF-1 elevation correlates with accelerated collagen synthesis, enhanced satellite cell activation in skeletal muscle, and increased fibroblast proliferation.
Research evaluating the somatotrophic axis also utilizes CJC-1295 to study feedback inhibition kinetics. Extended exposure to GHRH agonists alters pituitary somatotroph responsiveness and ghrelin receptor co-activation dynamics. Researchers investigating these continuous versus pulsatile signaling cascades frequently compare CJC-1295 against non-DAC variants to map receptor desensitization thresholds.
For additional context on how GHRH dynamics intersect with other secretagogue classes, refer to our educational deep-dive on GHRH analogs and cellular mechanics.
Understanding where CJC-1295 sits within the landscape of growth hormone secretagogues requires evaluating related compounds in the same functional class. GHRH analogs target the GHRH receptor directly, whereas Growth Hormone Releasing Peptides (GHRPs) or Growth Hormone Secretagogues (GHSs) act via the growth hormone secretagogue receptor (GHSR-1a).
When designing comparative secretagogue protocols, investigators often evaluate CJC-1295 alongside Ipamorelin, a highly selective GHSR-1a agonist, Sermorelin, an unmodified GHRH 1-29 fragment with rapid clearance dynamics, and Tesamorelin, a trans-3-hexenoic acid modified GHRH derivative specialized for lipid metabolism research. While CJC-1295 DAC provides unique extended half-life kinetics, combining GHRH analogs with selective GHRPs in vitro frequently demonstrates synergistic GH release amplitudes greater than the sum of individual secretagogue responses.
Because synthetic peptide manufacturing can yield incomplete sequences, deletion peptides, or residual protecting groups, evaluating CJC-1295 price requires strict scrutiny of analytical documentation. A reliable research supplier must provide comprehensive certification for every single production lot.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the gold standard for quantifying chemical purity. Chromatographic profiles should demonstrate a single, sharp main peak with an integrated area exceeding 98.0%. Electrospray Ionization Mass Spectrometry (ESI-MS) must be performed concurrently to verify molecular mass, ensuring the observed mass-to-charge (m/z) ratio corresponds precisely to the theoretical molecular weight of CJC-1295 (C152H252N44O42 for CJC-1295 DAC).
Acquiring unverified peptides risks introduced experimental artifacts caused by truncated peptide impurities. For full access to verified analytical data across our catalog, explore the complete range of research peptides available for laboratory purchase.
In cell culture assays and sensitive preclinical animal models, bacterial endotoxins (lipopolysaccharides) pose a severe confounding variable. Endotoxin contamination can trigger non-specific inflammatory responses, alter gene expression profiles, and induce cellular cytotoxicity, completely invalidating experimental results.
PX1 Research enforces stringent endotoxin limits across all peptide lots, using Limulus Amebocyte Lysate (LAL) testing under USP <85> guidelines. Ensuring bioburden levels remain below strict EU/mg thresholds is critical for reproducible in vitro secretagogue research. Suppliers offering low-cost reagents without verified endotoxin data expose research projects to unquantified biological noise.
To maintain structural integrity during reconstitution, CJC-1295 lyophilized powder should be handled in accordance with standard laboratory biophysical protocols. Reconstitution should occur using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline, depending on assay sensitivity to preservative agents.
The lyophilized cake should be allowed to reach room temperature before adding the diluent down the glass vial wall to prevent shear stress on the peptide structure. Gentle swirling is recommended; vigorous agitation or vortexing can cause peptide aggregation or denaturation. Reconstituted solutions should be aliquoted into low-protein-binding microcentrifuge tubes to prevent adsorption loss and stored at -20°C or -80°C for long-term stability.
For additional guidance on solvent compatibility, solubility parameters, and synergistic dosing paradigms in laboratory settings, review our guide on Ipamorelin and CJC-1295 laboratory synergy protocols.
The true cost of a research peptide extends beyond initial unit price to encompass supply chain reliability, shipping speed, and regulatory compliance. Substandard international sourcing often involves inconsistent synthesis runs, lack of lot traceability, and thermal degradation during prolonged international transit.
PX1 Research mitigates these risks by maintaining USA-based manufacturing and distribution operations. All orders are dispatched directly from facilities in California and Arizona, offering same-day shipping for orders placed Monday through Friday. This centralized domestic footprint preserves cold-chain integrity and eliminates extended transit delays, ensuring that researchers receive stable, highly active compounds ready for immediate laboratory preparation.
Why does CJC-1295 price vary significantly between suppliers?
Pricing variations reflect differences in synthesis scale, chemical purity, DAC modification, and analytical verification standards. High-purity peptides backed by ISO 17025 lab testing, third-party RP-HPLC/MS reports, and strict endotoxin screening incur higher manufacturing costs than unverified materials.
What is the structural difference between CJC-1295 DAC and CJC-1295 No DAC?
CJC-1295 DAC includes a maleimidopropionic acid reactive group that forms a covalent bond with plasma albumin, extending its biological half-life to several days in preclinical models. CJC-1295 No DAC lacks this linker, resulting in rapid enzymatic clearance and short-acting pulsatile signaling.
How is CJC-1295 purity verified at PX1 Research?
Every lot of CJC-1295 undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm ≥98% purity and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify molecular mass integrity, documented on an accompanying lot-specific Certificate of Analysis.
What endotoxin controls are applied to PX1 CJC-1295 batches?
All batches undergo rigorous Limulus Amebocyte Lysate (LAL) testing under USP <85> protocols to ensure endotoxin levels remain below strict research-grade thresholds, preventing non-specific immune activation in experimental models.
How should lyophilized CJC-1295 be stored upon receipt?
Lyophilized CJC-1295 should be stored at -20°C in a dry, dark environment. Upon reconstitution with sterile diluent, solution aliquots should be frozen at -20°C or -80°C to avoid repeated freeze-thaw cycles.
What GHRH receptor interactions are observed in preclinical studies?
Preclinical studies show that CJC-1295 selectively binds to somatotroph GHRH receptors, stimulating intracellular cAMP accumulation and downstream protein kinase A signaling to promote endogenous growth hormone secretion.
Can CJC-1295 be combined with GHRPs in experimental assays?
In preclinical research, co-administration of GHRH analogs like CJC-1295 with GHS/GHRP receptor agonists (such as Ipamorelin) demonstrates synergistic secretagogue activity, generating greater GH elevation than either class independently.
Does PX1 Research provide bulk pricing options for research institutions?
Yes, PX1 Research offers institutional pricing structures and bulk tier accounts for high-throughput laboratories and academic institutions requiring recurring volume supply.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.